Urenco Annual Report 2022

Financial statements Notes to the Company Financial Statements continued For the year ended 31 December 2022 2. Employee benefits expense continued Their aggregate remuneration comprised: Year ended 31/12/22 €m Year ended 31/12/21 €m Wages and salaries 34.1 30.3 Social security costs 3.8 3.1 Pension costs 2.3 1.6 40.2 35.0 Directors’ emoluments (page 74): Year ended 31/12/22 €m Year ended 31/12/21 €m Emoluments 3.2 2.9 Amounts receivable under long term incentive scheme 1.4 0.8 Number Number Members of defined contribution schemes 2 2 In respect of the highest paid Director: Year ended 31/12/22 €m Year ended 31/12/21 €m Emoluments including pension 2.2 1.6 3. Taxation Deferred tax Deferred tax balances recognised at 31 December 2022 and 31 December 2021 are as follows: 2022 €m 2021 €m Relating to property, plant and equipment and intangible assets (1.9) (2.5) Relating to tax losses 14.7 13.9 Relating to short term temporary differences 1.6 5.8 Relating to fair value movements on financial instruments 4.1 9.7 Relating to retirement benefits (2.6) (1.9) Total deferred tax asset 15.9 25.0 The deferred tax charge recognised in the income statement was €8.8 million (2021: tax credit €1.9 million). The Directors consider that the deferred tax assets are recoverable in full based on the company’s ability to surrender tax losses for payment via group relief. 4. Dividends paid and proposed Year ended 31/12/22 €m Year ended 31/12/21 €m Declared and paid during the year Amounts recognised as distributions to equity holders in the year: Final dividend for the year ended 31 December 2021 of 89.29 cents per share (2020: 89.29 cents per share) 150.0 150.0 Interim dividend for the year ended 31 December 2022 of 89.29 cents per share (2021: 89.29 cents per share) 150.0 150.0 300.0 300.0 Proposed for approval at the Annual General Meeting Proposed final dividend for the year ended 31 December 2022 of 89.29 cents per share (2021: 89.29 cents per share) 150.0 150.0 The 2022 final dividend of €150 million is subject to approval by shareholders at the Annual General Meeting on 8 March 2023 and has not been included as a liability in these financial statements. 171 Urenco Annual report and accounts 2022 Financial statements 03